Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and ...

Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as ...

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient ...

Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.

BMS’s Kevin Cook explains why digital capability is becoming a must-have for strategic CMO partners and why the next phase ...

Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management ...

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean ...

A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.

Real-world evidence is increasingly valuable when it measurably changes clinical actions, not only when it supports publications, retrospective analyses or regulatory submissions. Information overload ...

DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years ...

ELPRO CEO Frederik Dresen explains how cold chain monitoring moved from compliance to risk management, and what biologics and advanced therapies demand. The pharmaceutical cold chain has evolved from ...